Eli Lilly is gearing up to transform obesity treatment with innovative drugs such as Mounjaro and Zepbound, and now a forthcoming oral medication, orforglipron, that rivals Novo Nordisk's Ozempic. The company’s focus is to revolutionize how weight management is approached, looking toward a future where people can receive a yearly injection for weight loss similar to seasonal vaccinations. Patrik Jonsson, the head of obesity at Eli Lilly, highlights the potential of this annual solution to enhance patient compliance and improve outcomes significantly.
Eli Lilly's Patrik Jonsson envisions a future where patients receive a yearly weight-loss shot, revolutionizing just-in-time obesity care similar to flu vaccines.
The ultimate goal at Eli Lilly is to develop a once-per-year injectable solution that profoundly impacts weight management and aligns with patients' healthcare routines.
Collection
[
|
...
]